Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib immunomodulatory activity in solid tumors
NCT02304419Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of galunisertib in solid tumor, sponsored by Eli Lilly and Company. Primary endpoints: Change from Baseline in Immune Cell Subsets at Cycle 6, Change from Baseline in Serum Cytokines at Cycle 6 and 1 more. Started May 2015; status: completed.
02
Drugs
galunisertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02304419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02304419.